Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
767.76
+10.22 (1.35%)
Dec 20, 2024, 4:00 PM EST - Market closed
Eli Lilly Revenue
Eli Lilly had revenue of $11.44B in the quarter ending September 30, 2024, with 20.43% growth. This brings the company's revenue in the last twelve months to $40.86B, up 27.41% year-over-year. In the year 2023, Eli Lilly had annual revenue of $34.12B with 19.56% growth.
Revenue (ttm)
$40.86B
Revenue Growth
+27.41%
P/S Ratio
16.92
Revenue / Employee
$950,309
Employees
43,000
Market Cap
691.32B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
Dec 31, 2019 | 22.32B | 826.20M | 3.84% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 393.90B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher | 42.37B |
Abbott Laboratories | 41.22B |
LLY News
- 1 day ago - Zepbound Approved For Sleep Apnea - Forbes
- 1 day ago - Lilly's weight-loss drug Zepbound wins US FDA approval for sleep apnea - Reuters
- 1 day ago - FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S. - CNBC
- 1 day ago - FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity - PRNewsWire
- 1 day ago - Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now - Seeking Alpha
- 1 day ago - Indiana Sees $39 Billion Worth of Projects Under Construction, an Industrial Info News Alert - Business Wire
- 1 day ago - Novo Nordisk Stock Crashes 22% After Disappoitning Obesity Drug Data. Eli Lilly Shares Soar. - Barrons
- 2 days ago - Focus: In weight loss battle, Novo and Lilly face growing offensive from licenced copies - Reuters